Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

Watson Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited; in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Net revenues $622,636 $603,005 $1,249,585 $1,274,610

Cost of sales (excludes

amortization, presented below) 359,898 360,438 740,000 785,158

Gross profit 262,738 242,567 509,585 489,452

Operating expenses:

Research and development 39,216 35,503 77,231 73,311

Selling, general and

administrative 104,295 97,158 210,928 200,376

Amortization 20,190 44,159 40,369 88,092

Total operating expenses 163,701 176,820 328,528 361,779

Operating income 99,037 65,747 181,057 127,673

Non-operating (expense)

income, net:

Loss on early extinguishment

of debt - (1,681) (1,095) (4,410)

Interest income 1,685 1,803 3,994 4,732

Interest expense (6,931) (11,475) (13,727) (25,351)

Other income 2,080 3,034 7,433 6,437

Total non-operating expense,

net (3,166) (8,319) (3,395) (18,592)

Income before income taxes 95,871 57,428 177,662 109,081

Provision for income taxes 35,568 21,019 66,730 41,060

Net income $60,303 $36,409 $110,932 $68,021

Diluted earnings per share $0.53 $0.33 $0.98 $0.62

Diluted weighted a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... India , June 19, ... Bharat Book Bureau presents Innovative ... and Formulation Technology Licensing Opportunities ... http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html ) There ... or controlled release drugs approved ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
(Date:6/18/2013)... In support of Swiss contributions to scientific ... Switzerland in New York is pleased to welcome the ... , to Manhattan. PlanetSolar is in New York ... with scientists on board from the University of Geneva. ... on energy from the sun and eliminates the need ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s ... National AgriScience Teachers Ambassador Academy this week (NATAA) at ... , The NATAA “Ag Academy” is a ... special project of the National FFA Foundation ... . The highly recommended agriscience teachers, who are ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3
... German . , Automation makes a business competitive ... small and medium-sized enterprises (SMEs). However, for many SMEs, ... too big or too expensive. SMErobot now promises to ... in small and medium-sized businesses: this EU project is ...
... 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, will announce its fourth ... market open on,Wednesday, March 5, 2008. The Company ... these results later that same day at 10:00 ...
... KOSN ) today reported financial results for the,quarter and year ... and year ended December 31, 2007 were $9.5,million and $28.7 ... and $29.5 million, or $0.13 and $0.88 per share, in ... million and $22.7 million for the quarter and year,ended December ...
Cached Biology Technology:SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 2SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 3SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 2Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 5Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 6
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
(Date:6/18/2013)... of internationally recognized feline experts including veterinarians and feline ... of Lincoln, U.K. and Dr Ilona Rodan, Director of ... International Society of Feline Medicine (ISFM) and the American ... veterinarians, owners and those working with cats on how ... The new guidelines appear in the Journal of ...
(Date:6/17/2013)... to high levels of air pollution while pregnant were up ... as women who lived in areas with low pollution, according ... (HSPH). It is the first large national study to examine ... "Our findings raise concerns since, depending on the pollutant, 20% ... areas where risk of autism was elevated," said lead author ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... Mont. -- Natural barriers like waterfalls play an important ... National Park, so maintaining those barriers should be a ... four-year study in the park. Park workers might ... the water from rising behind those barriers, said graduate ...
... more than 300 leading European and Chinese scientists have ... in the Peoples Republic of China to present their ... Dragon 2. The Dragon Programme is a joint ... Technology (MOST) of China designed to encourage increased exploitation ...
... (April 24, 2008) The Wildlife Conservation Society (WCS) ... change is affecting populations of a quintessential Arctic denizen: ... the National Park Service, U. S. Geological Survey, and ... already equipped six musk ox with GPS collars to ...
Cached Biology News:Montana State researchers study spread of lake trout in Glacier National Park 2Successful cooperation extends Dragon Program 2Successful cooperation extends Dragon Program 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: